Cheraghali Abdol Majid, Abolghasemi Hassan
Iranian Blood Transfusion Organization Research Center, Tehran, Iran.
Biologicals. 2010 Jan;38(1):81-6. doi: 10.1016/j.biologicals.2009.10.004.
Plasma contains several therapeutically important proteins. Currently more than 25 of them are commercially available to treat life-threatening diseases. Some of these medicines already included in the WHO Model List of Essential Medicines indicating their importance from a global perspective. However, unfortunately due to very high cost of treatment with plasma-derived medicines, these clinically precious tools are not affordable for a majority of the patients living in developing countries. There are some options available for securing accessibility to these medicines. These include local production, importation and contract fractionation of locally produced plasma. Although local production of plasma-derived medicines and/or importation of these medicines might be a practical approach to respond to the needs for these medicines, in recent years several countries have used contract fractionation of locally produced plasma as a very effective approach for improving availability and affordability of plasma-derived medicines in their national market.
血浆含有几种具有重要治疗意义的蛋白质。目前，其中有25种以上已在商业上用于治疗危及生命的疾病。这些药物中的一些已被列入世界卫生组织基本药物示范清单，从全球角度表明了它们的重要性。然而，不幸的是，由于血浆衍生药物的治疗成本非常高，这些临床上珍贵的工具对于大多数生活在发展中国家的患者来说是负担不起的。有一些确保获得这些药物的选择。这些选择包括本地生产、进口以及对本地生产的血浆进行合同分馏。尽管本地生产血浆衍生药物和/或进口这些药物可能是满足这些药物需求的一种实际方法，但近年来，一些国家已将对本地生产的血浆进行合同分馏作为提高其国内市场血浆衍生药物的可及性和可负担性的一种非常有效的方法。
